| review article | Q7318358 |
| scholarly article | Q13442814 |
| P8150 | COVIDWHO ID | covidwho-116711 |
| P6179 | Dimensions Publication ID | 1127135825 |
| P356 | DOI | 10.1016/J.ANPEDI.2020.04.016 |
| P932 | PMC publication ID | 7183283 |
| P698 | PubMed publication ID | 32439309 |
| P8299 | Semantic Scholar corpus ID | 216128418 |
| P2093 | author name string | Alberto García-Salido | |
| P2860 | cites work | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 |
| Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Q87281430 | ||
| Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Q87412594 | ||
| Critical care management of adults with community-acquired severe respiratory viral infection | Q87461636 | ||
| COVID-19: combining antiviral and anti-inflammatory treatments | Q87865652 | ||
| Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial | Q87908797 | ||
| A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Q88370045 | ||
| Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy | Q88401707 | ||
| Reducing mortality from 2019-nCoV: host-directed therapies should be an option | Q89606283 | ||
| Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series | Q89787863 | ||
| Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China | Q89796088 | ||
| The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? | Q89840059 | ||
| Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic | Q89913973 | ||
| On the use of corticosteroids for 2019-nCoV pneumonia | Q89981025 | ||
| Hematologic parameters in patients with COVID-19 infection | Q90027025 | ||
| A potential role for integrins in host cell entry by SARS-CoV-2 | Q90045007 | ||
| The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China | Q90089468 | ||
| Arguments in favour of remdesivir for treating SARS-CoV-2 infections | Q90138891 | ||
| Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States | Q90235789 | ||
| The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options | Q90243955 | ||
| Dysregulation of immune response in patients with COVID-19 in Wuhan, China | Q90251434 | ||
| Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19 | Q90263766 | ||
| Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? | Q90292620 | ||
| Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China | Q90296811 | ||
| Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms | Q90298818 | ||
| Estimating Risk for Death from 2019 Novel Coronavirus Disease, China, January-February 2020 | Q90305059 | ||
| The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status | Q90310442 | ||
| A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 | Q90335371 | ||
| Treatment of COVID-19: old tricks for new challenges | Q90364890 | ||
| Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Q90702138 | ||
| The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study | Q90709473 | ||
| Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 | Q90717662 | ||
| Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients | Q90757778 | ||
| Coronavirus infections and immune responses | Q92935501 | ||
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| P577 | publication date | 2020-04-25 | |
| 2020-07-01 | |||
| P1433 | published in | Anales de Pediatria Continuada | Q15760182 |
| Anales de Pediatría (English Edition) | Q68171704 | ||
| P1476 | title | [Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications] |
Search more.